The present disclosure provides gene edited modified immune cells or precursors thereof (e.g., gene edited modified T cells) comprising an exogenous T cell receptor (TCR) and/or a chimeric antigen receptor (CAR) having specificity for a target antigen, and an insertion and/or deletion in one or more endogenous gene loci, wherein the endogenous gene loci encode regulators of T cell function, thereby resulting in immune cells having enhanced function. Compositions and methods of treatment are also provided. The present invention provides methods of screening for TCR- or CAR-T cells with enhanced immune function (e.g., T cell efficacy, T cell memory, and/or T cell persistence).

The present disclosure provides engineered immune cells and methods for their creation and use. The immune cells comprise activating and blocking receptors, in which the blocking receptor provides a signal that dominates a signal from the activating receptor.

The present disclosure relates generally to methods of producing rejuvenated T cells, comprising, contacting T cells with at least one reprogramming factor and reactivating the contacted cells; and compositions and methods of using same. The present disclosure also describes cell populations prepared according to methods described herein. The disclosure also provides for methods of treating patients using cell populations prepared by the methods described herein.

The present invention includes compositions and methods for a modified immune cell or precursor cell thereof comprising an inducible expression system. Also provided are gene edited modified immune cells suitable for T cell therapy. Methods of treatment using modified immune cells of the present invention are also provided.

Provided are systems for modifying a cell. Also provided are methods for using the systems for modifying a cell.

The present invention provides a method of treating a cancer in an individual using activated T cells or PBMCs induced by antigen presenting cells (such as dendritic cells) loaded with a plurality of tumor antigen peptides. The method may further comprise administration of the antigen presenting cells loaded with the plurality of tumor antigen peptides to the individual. The methods may be used singly or in combination with an immune checkpoint inhibitor. Precision therapy methods customized for the individual using neoantigen peptides or based on the mutation load in the tumor of the individual are provided. Methods of preparing the activated T cells, methods of monitoring the treatment, and methods of cloning tumor-specific T cell receptors are further disclosed. An isolated population of cells comprising the activated T cells, as well as compositions and kits useful for cancer immunotherapy are also provided.

The present disclosure relates to engineered T cells and methods of making and using the same, as well as reagents for making the engineered T cells.

Combinations comprising one or more nucleic acid molecules comprising a nucleic acid sequence A encoding for a TCR alpha chain linked to a dimerization domain, and a nucleic acid sequence B encoding for a TCR beta chain linked to a dimerization domain, as well as proteins encoded by such nucleic acid molecules and corresponding uses and methods.

The present invention relates to a chimeric antigen receptor having a ligand specifically targeting an anthrax toxin receptor (ANTXR), and, more specifically, to: a nucleic acid encoding a chimeric antigen receptor comprising ligand PA63 specifically binding to anthrax toxin receptor 1 (ANTXR1) or anthrax toxin receptor 2 (ANTXR2); a vector comprising the nucleic acid encoding a chimeric antigen receptor; and a recombinant cell comprising the vector; a pharmaceutical composition for preventing or treating solid cancer, comprising the recombinant cell; and a treatment method. Solid cancer can be treated using an anti-ANTXR chimeric antigen receptor (CAR)-T cell, according to the present invention, and since the chimeric antigen receptor (CAR)-T cell is administered to patients with solid cancer for whom anti-cancer drug administration is not effective, especially patients with pancreatic cancer, drug administration is limited, and customized solid cancer prevention or treatment, which are efficient and safe, is possible.

Provided herein are nucleic acids, expression cassettes, modified lymphocytes and compositions comprising the same which include a sequence encoding a fusion protein, TCR or CAR that includes a domain of LTBR. In certain embodiments, the cell is a T cell. Methods of treatment using the provided compositions are also described.